Steven Cohen Jounce Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $13,650 - $24,600	5,000 Added 1.7%	299,731 $701,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $27,720 - $75,933	9,900 Added 3.48%	294,731 $893,000
Q1 2022 May 16, 2022	BUY	$6.01 - $8.54 $185,709 - $263,886	30,900 Added 12.17%	284,831 $1.93 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $1.81 Million - $2.45 Million	253,931 New	253,931 $2.12 Million
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $582,000 - $1.74 Million	-200,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $562,000 - $1.84 Million	200,000 New	200,000 $1.75 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.